Hence, our study provides compelling evidence that XBP1s plays a crucial role in the progression of HR+/HER2− breast cancer and contributes to the development of resistance to the combined treatment of CDK4/6 inhibitors plus endocrine therapy. This evidence concerns the gene CDK4 and breast carcinoma.